Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
WENZEL, S. E., SCHWARTZ, L. B., LANGMACK, E. L., HALLIDAY, J. L., TRUDEAU, J. B., GIBBS, R. L., & CHU, H. W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9812110 · Cited by 1,235
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Neuropsychopharmacology: The Fifth Generation of Progress
SAGDUYU, K. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1251-a · Cited by 1,019
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Woodruff, P. G., Boushey, H. A., Dolganov, G. M., Barker, C. S., Yang, Y. H., Donnelly, S., Ellwanger, A., Sidhu, S. S., Dao-Pick, T. P., Pantoja, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707413104 · Cited by 828
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Neuropsychopharmacology : The Fifth Generation of Progress
Davis, K. L., Charney, D. S., Coyle, J. T., & Nemeroff, C. B. (2002) · Lippincott Williams & Wilkins eBooks · Cited by 747
Prostaglandin D 2 as a Mediator of Allergic Asthma
Matsuoka, T., Hirata, M., Tanaka, H., Takahashi, Y., Murata, T., Kabashima, K., Sugimoto, Y., Kobayashi, T., Ushikubi, F., Aze, Y., et al. (2000) · Science · doi:10.1126/science.287.5460.2013 · Cited by 743
Phase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697 · cited 1×
“20 (9) Indication selected does not fit strongest preclinical evidence”
BackgroundMorgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Self-citationSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401
Glutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
Self-citation[Apolipoprotein E polymorphism and Alzheimer disease].
van der Weide, J., Steijns, L. S. W., Jl, T., Wj, N., & Klaverwijden, G. (1996) · PubMed · Cited by 297
The sequence of events that underlie quantal transmission at central glutamatergic synapses
Lisman, J. E., Raghavachari, S., & Tsien, R. W. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2191 · Cited by 247
Of Mice and Humans: Are They the Same?—Implications in Cancer Translational Research: TABLE 1
de Jong, M., & Maina, T. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.065706 · Cited by 228
Evidence for Ordering of Alzheimer Disease Biomarkers
Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 223
SPASTIC PARAPARESIS: A POSSIBLE SEXUALLY TRANSMITTED VIRAL MYELONEUROPATHY
ZANINOVIC, V (1986) · The Lancet · doi:10.1016/s0140-6736(86)90217-5 · Cited by 221
Barnes, N., Pavord, I., Chuchalin, A., Bell, J., Hunter, M., Lewis, T., Parker, D., Payton, M., Collins, L. P., Pettipher, R., et al. (2012) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03813.x · Cited by 218
Holgate, S. T. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.052 · Cited by 163
Market withdrawal of new molecular entities approved in the United States from 1980 to 2009
Qureshi, Z. P., Seoane-Vazquez, E. C., Rodríguez-Monguió, R., Stevenson, K., & Szeinbach, S. L. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2155 · Cited by 157
Prevention of Allergic Inflammation by a Novel Prostaglandin Receptor Antagonist, S-5751
Arimura, A., Yasui, K., Kishino, J., Asanuma, F., Hasegawa, H., Kakudo, S., Ohtani, M., & Arita, H. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29398-8 · Cited by 157
Olsson, G. O., Blasetto, J. W., Bryzinski, B. S., Caplan, R. J., & Gold, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14934-3 · Cited by 140
Assessing the translatability of drug projects: what needs to be scored to predict success?
Wehling, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2898 · Cited by 121
Mealing, G. A. R., Lanthorn, T. H., Murray, C. L., Small, D. L., & Morley, P. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37943-1 · Cited by 113
Prahalad, S. (2006) · Genes and Immunity · doi:10.1038/sj.gene.6364298 · Cited by 108
The translatability of animal models for clinical development: biomarkers and disease models
Wendler, A., & Wehling, M. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.05.009 · Cited by 103
Vierboom, M., Zavodny, P. J., Chou, C., Tagat, J. R., Pugliese‐Sivo, C., Strizki, J., Steensma, R. W., McCombie, S. W., Paul, A., Remarque, E. J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20850 · Cited by 99
Thébault, J. J., Guillaume, M., & Levy, R. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.14.1295.43156 · Cited by 98
Lip, G. Y. H., Rasmussen, L. H., Olsson, S., Jensen, E. C., Persson, A., Eriksson, U. G., & Wåhlander, K. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp318 · Cited by 97
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients
Busse, W. W., Wenzel, S. E., Meltzer, E. O., Kerwin, E., Liu, M. C., Zhang, N., Chon, Y., Budelsky, A., Lin, J., & Lin, S. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.10.013 · Cited by 91
Does size matter in R&D productivity? If not, what does?
Ringel, M. S., Tollman, P., Hersch, G. L., & Schulze, U. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4164 · Cited by 89 · cited 3×
“All rights reserved Nature Reviews | Drug Discovery a Reasons for lack of clinical efficacy b Phase II projects 0 100 Yes (15) No (21) R at io o f p ro je ct s (% ) Active or successfulClosed 27 73 57 43 40 (18)Target linkage to disease not establishedor no validated models available 29 (13)Dose limited by compound ch…”
BackgroundIn-vitro assessment of platelet function
Picker, S. M. (2011) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2011.03.006 · Cited by 84
Model-based drug discovery: implementation and impact
Visser, S. A. G., Aurell, M., Jones, R. D. O., Schuck, V., Egnell, A., Peters, S. A., Brynne, L., Yates, J. W. T., Jansson‐Löfmark, R., Tan, B., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.012 · Cited by 70
CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial
van Kuijk, A. W. R., Vergunst, C. E., Gerlag, D. M., Bresnihan, B., Gómez-Reino, J. J., Rouzier, R., Verschueren, P., van der Leij, C., Maas, M. M., Kraan, M. C., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.131235 · Cited by 70
Fleishaker, D. L., Meijide, J. A. G., Av, P., Kohen, M. D., Wang, X., Menon, S. S., Stock, T. C., Mebus, C. A., Goodrich, J. M., Mayer, H., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3685 · Cited by 68 · cited 1×
“Yes (15) No (21) R at io o f p ro je ct s (% )”
Gerlag, D. M., Hollis, S., Layton, M., Vencovský, J., Szekanecz, Z., Braddock, M., Tak, P. P., & ESCAPE Study Group (2010) · Arthritis & Rheumatism · doi:10.1002/art.27652 · Cited by 68
Lukacs, N. W., Berlin, A. A., Franz-Bacon, K., Šášik, R., Sprague, L. J., Ly, T. W., Hardiman, G., Boehme, S. A., & Bacon, K. B. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90351.2008 · Cited by 67
Ramsey, S. J., Attkins, N., Fish, R. L., & van der Graaf, P. H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01390.x · Cited by 56
Freedman, N. M. T., Mishani, E., Krausz, Y., Weininger, J., Lester, H., Blaugrund, E., Ehrlich, D., & Chisin, R. (2005) · PubMed · Cited by 56
The industrialization of drug discovery
Handen, J. S. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02099-2 · Cited by 54
Gervais, F. G., Sawyer, N., Stocco, R., Hamel, M., Krawczyk, C. M., Sillaots, S., Denis, D., Wong, E., Wang, Z., Gallant, M., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068585 · Cited by 54
Clinical attrition due to biased preclinical assessments of potential efficacy
Lindner, M. D. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.05.002 · Cited by 52
Rasmussen, L. E., Tveit, A., Jensen, E. C., Wessman, P., Panfilov, S., Wåhlander, K., & Olsson, B. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-07-0509 · Cited by 52 · cited 1×
“Preclinical Phase I Phase II Phase III Preclinical (33) Phase I (27) Phase IIa (26) Phase IIb (8) b Project closures”
BackgroundIL-13: A Promising Therapeutic Target for Bronchial Asthma
Kanaji, T., Ohta, S., Kanaji, S., Arima, K., & Izuhara, K. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777935140 · Cited by 52
Microarray-based Identification of Novel Biomarkers in Asthma
Izuhara, K., & Saito, H. (2006) · Allergology International · doi:10.2332/allergolint.55.361 · Cited by 44
Lebrikizumab in the personalized management of asthma
Thomson, N. C., Patel, M., & Smith, A. D. (2012) · Biologics · doi:10.2147/btt.s28666 · Cited by 40
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.5505 · Cited by 40
Redfern, W. S., Bialecki, R., Ewart, L. C., Hammond, T. G., Kinter, L. D., Lindgren, S., Pollard, C. E., Rolf, M. G., & Valentin, J. (2010) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2010.11.098 · Cited by 34
The Use of Imaging in the Early Development of Neuropharmacological Drugs: A Survey of Approved NDAs
Uppoor, R. S., Mummaneni, P., Cooper, E., Pien, H., Sorensen, A. G., Collins, J. M., Mehta, M., & Yasuda, S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100422 · Cited by 31
Neuropsychiatric adverse effects signal the end of the line for rimonabant
King, A. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.148 · Cited by 24
Drug-mediated toxicity: illuminating the ‘bad’ in the test tube by means of cellular assays?
Tralau, T., & Luch, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.015 · Cited by 24
A prostaglandin D2receptor antagonist modifies experimental asthma in sheep
Shichijo, M., Arimura, A., Hirano, Y., Yasui, K., Suzuki, N., Deguchi, M., & Abraham, W. M. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03275.x · Cited by 24
A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats
Okamoto, H., & Kamatani, N. (2005) · Rheumatology · doi:10.1093/rheumatology/kei213 · Cited by 23
Pehrsson, S., Johansson, K., Kjaer, M., & Elg, M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-10-0744 · Cited by 13
Wolzt, M., Eriksson, U. G., Gouya, G., Leuchten, N., Kapiotis, S., Elg, M., Schützer, K.-M., Zetterstrand, S., Holmberg, M., & Wåhlander, K. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.08.018 · Cited by 6
[Clarification of the pathogenesis and development of clinical examination for allergic diseases].
Izuhara, K., Kanaji, S., Ohta, S., & Arima, K. (2007) · PubMed · Cited by 2
Experimental medicine model shows no depressogenic effects of varenicline
Pringle, A., Mocking, R. J. T., Pflanz, C. P., Parsons, L. H., McTavish, S. F. B., Cowen, P. J., & Harmer, C. N. (2012) · The International Journal of Neuropsychopharmacology · Cited by 1
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Applications of Fluorine in Medicinal Chemistry
Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00258 · Cited by 3,618
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
“Clinical trials are complex and expensive, and pre-clinical data that helps stratify patients can dramatically increase the likelihood of success during clinical development (Cook et al., 2014; Nelson et al., 2015).”
BackgroundGenome-wide association studies
Uffelmann, E., Huang, Q. Q., Munung, N. S., de Vries, J., Okada, Y., Martin, A. R., Martin, H. C., Lappalainen, T., & Posthuma, D. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00056-9 · Cited by 1,849
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.